News | January 22, 2009

Atrium Medical Completes Enrollment for Evaluation of Voclosporin-Coated Coronary Stent

January 23, 2009 - Isotechnika Inc. said yesterday that partner Atrium Medical Corp. has completed patient enrollment for their CONFIRM 1, First-in-Man (FIM) drug-coated coronary stent clinical trial evaluating Atrium's CINATRA voclosporin-coated coronary stent system.

The prospective, multi-center, single blind, randomized, controlled study will compare the CINATRA voclosporin-coated coronary stent system with Atrium's CINATRA bare metal coronary stent (BMS) platform. This first use study of voclosporin on an implantable medical device enrolled 100 patients and is currently being conducted at seven hospitals in Belgium with Glenn Van Langenhove, M.D., PhD of Middelheim Hospital, Antwerp, as the study's principal investigator. The primary endpoint of the trial is to evaluate the safety and performance of the CINATRA voclosporin-coated coronary stent system in patients with de novo coronary artery disease. Patient outcomes, in addition to drug coated stent performance, will be assessed by measuring late lumen loss, in-stent and in-segment lumen loss measurements at six months following implantation.

The CINATRA Voclosporin-Coated Coronary Stent System is comprised of a cobalt chromium bare metal stent mounted on a delivery balloon catheter. The stent and the balloon are coated with Atrium's proprietary Omega-3 fatty acid coating technology utilizing voclosporin for its anti-inflammatory properties.

For more information: www.isotechnika.com, www.atriummed.com

Related Content

News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
News | Stents Drug Eluting

January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...

Home January 26, 2021
Home
Videos | Stents Drug Eluting

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
News | Stents Drug Eluting

October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet ...

Home October 16, 2020
Home
News | Stents Drug Eluting

October 11, 2019 — The ultra-thin Supraflex drug-eluting stent (DES) from SMT maintained numerically lower outcomes at ...

Home October 11, 2019
Home
News | Stents Drug Eluting

September 30, 2019 – The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug ...

Home September 30, 2019
Home
News | Stents Drug Eluting

September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual ...

Home September 30, 2019
Home
News | Stents Drug Eluting

September 5, 2019 — Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target ...

Home September 05, 2019
Home
News | Stents Drug Eluting

October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer ...

Home October 01, 2018
Home
Subscribe Now